VANCOUVER, B.C.—Hospital inpatient costs were more than $10,000 less for patients treated with nasal metoclopramide than for those given oral metoclopramide in a study presented at the 2023 annual meeting of the American College of Gastroenterology.
“These data offer real-world evidence for healthcare providers and payors, emphasizing the substantial benefits of the nasal route for treating patients with diabetic gastroparesis,” said lead investigator Richard W. McCallum, MD,